久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Companies

Merck Serono looks to expand value chain

By Liu Jie (China Daily)
Updated: 2011-03-29 13:23
Large Medium Small

BEIJING - The biopharmaceutical company Merck Serono AG says mergers and acquisitions (M&A) will play a part in its development strategy in China, as the company seeks to complete its industry value chain and expand into the grassroots market.

Howard Sui, chairman and president of Merck Serono China Co Ltd, told China Daily on Monday that the company already has a research and development (R&D) center and a trading company in China, and is now seeking businesses engaged in manufacturing and distribution.

"We are selecting information and have had contact with some Chinese companies, but no decision has yet been made," said Sui.

Merck Serono looks to expand value chain

Howard Sui, chairman and president of Merck Serono China Co Ltd

Merck Serono, the prescription medicine division of the global pharmaceuticals and chemicals group Merck KGaA, has annually maintained sales growth of more than 30 percent in China since entering the market in 2007.

Merck Serono set up a trading company in Beijing with an investment of 300 million yuan ($45 million). Its Asian R&D center was established in November 2009, at a cost of 150 million euros ($211 million).

However, the company has no production capability in China, because it lacks the facilities in the market.

"We plan to establish a manufacturing facility in Beijing later this year after a decision was made when the group's senior executives visited China in 2010. The internal approval procedure is expected to be finalized next month," said Sui, without revealing the amount of investment in the new plant, or its production capability.

He also said that M&A activity will combine with organic growth to support the development of the company over the long term.

Merck Serono has introduced 18 drug brands in nine separate fields, treating conditions in the cardiovascular, thyroid, and women's health and fertility fields. The treatments are available at key hospitals in cities nationwide though partnerships with domestic distribution companies.

"If Merck Serono can buy a distributor, it will help the drugmaker to reach the grassroots markets at a relatively low cost," said Li Yu, a researcher at the Samsung Economic Research Institute China.

Related readings:
Merck Serono looks to expand value chain China lures global drug makers
Merck Serono looks to expand value chain Merck begins work on new unit
Merck Serono looks to expand value chain Lilly to continue China expansion
Merck Serono looks to expand value chain Novartis gets stake approval

Merck Serono's parent group has successfully employed an M&A strategy in China. In January, Merck KGaA bought Beijing Skywing Technology Co Ltd, a biopharmaceutical company, for 120 million yuan. In September 2009, it also acquired Suzhou Taizhu Technology Co Ltd, an effect pigment supplier based in Jiangsu province, for 28 million euros to expand its chemical business portfolio.

Merck KGaA has also been active in global M&A. Its latest move is the acquisition of Millipore Corp - a Massachusetts-based biopharmaceutical and life sciences company - in June.

That helped the German group lift its full-year profits and exceed analysts' expectations. The 2010 fiscal year saw post-tax profit climbing 70 percent to 642 million euros.

In 2007, Merck KGaA paid $13.3 billion to acquire Serono, at the time Europe's largest biopharmaceutical company by sales, and establish the Merck Serono joint venture. That deal helped the company to grow its China business by nine or 10 times between 2007 and 2009.

Multinational pharmaceutical companies have recently been conducting an aggressive M&A campaign in China. On March 22, the Swiss drugmaker Novartis AG announced that it had completed the acquisition of an 85 percent stake in Zhejiang-based Tianyuan Bio-Pharmaceutical Co Ltd for 850 million yuan.

France's Sanofi-Aventis SA bought BMP Sunstone Corporation for approximately $521 million in the largest M&A deal in China's pharmaceutical industry.

 

分享按鈕
主站蜘蛛池模板: 国产com| 欧美成人亚洲综合精品欧美激情 | 高清一区二区三区四区五区 | 无遮挡一级毛片私人影院 | 三级在线国产 | 日韩精品视频在线 | 国产成人3p视频免费观看 | 久久99国产亚洲高清观看韩国 | 日本三级成人中文字幕乱码 | 色综合a怡红院怡红院首页 色综合精品久久久久久久 色综合九九 | 草草伊人 | 72种姿势欧美久久久久大黄蕉 | 国产肥老妇视频一 | 欧美激情中文字幕 | 亚洲综合天堂网 | 成人免费手机在线看网站 | 成人公开免费视频 | 鲁老汉精品视频在线观看 | 欧美日韩一区二区三区视频 | 中文字幕最新中文字幕中文字幕 | 美女又黄又www | 亚洲欧美成人网 | 国产成人精品免费午夜 | 毛片视频在线免费观看 | 国产精品亚洲一区二区在线观看 | 一级毛片在线视频 | 一级看片免费视频囗交 | 黄色三级网络 | 中文字幕一区在线 | vvvv99日韩精品亚洲 | 日韩欧美精品一区二区 | 免费一级欧美大片久久网 | 日本亚洲免费 | 欧美日韩一区二区在线观看 | 一级毛片免费在线 | 国产毛片一级 | 亚洲欧美日韩高清在线看 | 91免费国产高清观看 | 欧美视频一区 | 亚洲国产精品自产拍在线播放 | 中文字幕视频免费在线观看 |